Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$12.63 - $24.47 $376,929 - $730,282
29,844 Added 30.01%
129,280 $3.05 Million
Q3 2023

Nov 15, 2023

BUY
$10.86 - $17.62 $671,213 - $1.09 Million
61,806 Added 164.25%
99,436 $1.48 Million
Q2 2023

Aug 11, 2023

BUY
$7.47 - $10.95 $23,343 - $34,218
3,125 Added 9.06%
37,630 $412,000
Q2 2022

Aug 15, 2022

SELL
$1.72 - $3.39 $59,348 - $116,971
-34,505 Closed
0 $0
Q1 2022

Aug 11, 2023

BUY
$2.77 - $3.64 $95,578 - $125,598
34,505 New
34,505 $107,000
Q1 2022

May 20, 2022

SELL
$2.77 - $3.64 $13,057 - $17,158
-4,714 Reduced 12.02%
34,505 $107,000
Q4 2021

Feb 16, 2022

BUY
$3.23 - $4.6 $54,738 - $77,956
16,947 Added 76.09%
39,219 $133,000
Q3 2021

Nov 12, 2021

SELL
$3.47 - $4.42 $71,034 - $90,481
-20,471 Reduced 47.89%
22,272 $81,000
Q2 2021

Aug 12, 2021

BUY
$3.94 - $4.92 $3,975 - $4,964
1,009 Added 2.42%
42,743 $186,000
Q1 2021

May 03, 2021

BUY
$4.23 - $6.55 $2,030 - $3,144
480 Added 1.16%
41,734 $189,000
Q4 2020

Feb 12, 2021

BUY
$5.73 - $9.03 $4,744 - $7,476
828 Added 2.05%
41,254 $237,000
Q3 2020

Nov 09, 2020

SELL
$3.32 - $7.24 $4,976 - $10,852
-1,499 Reduced 3.58%
40,426 $293,000
Q2 2020

Aug 10, 2020

SELL
$1.41 - $4.25 $6,395 - $19,278
-4,536 Reduced 9.76%
41,925 $149,000
Q1 2020

May 15, 2020

BUY
$1.25 - $2.02 $6,615 - $10,689
5,292 Added 12.85%
46,461 $69,000
Q4 2019

Feb 14, 2020

SELL
$1.33 - $5.93 $1,677 - $7,477
-1,261 Reduced 2.97%
41,169 $81,000
Q2 2019

Aug 14, 2019

BUY
$6.05 - $13.66 $28,610 - $64,598
4,729 Added 12.54%
42,430 $304,000
Q1 2019

May 13, 2019

BUY
$8.16 - $13.42 $8,037 - $13,218
985 Added 2.68%
37,701 $500,000
Q4 2018

Feb 14, 2019

SELL
$6.54 - $11.74 $7,632 - $13,700
-1,167 Reduced 3.08%
36,716 $289,000
Q3 2018

Nov 14, 2018

SELL
$10.88 - $14.52 $51,016 - $68,084
-4,689 Reduced 11.01%
37,883 $419,000
Q2 2018

Aug 14, 2018

BUY
$10.66 - $14.38 $453,817 - $612,185
42,572 New
42,572 $571,000

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.